| IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC (NCT05077709) | IO Biotech | 2022-04-11 |
| Neoadjuvant Immunotherapy in Advanced NSCLC (NCT05137912) | Power Life Sciences Inc. | 2022-02-01 |
| Shared Decision Making on Radiation Dose for Lung Malignancies (NCT04940936) | Vejle Hospital | 2021-11-12 |
| Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study) (NCT05598528) | Second Xiangya Hospital of Central South University | 2021-09-28 |
| Molecular Disease Characterization Initiative (MDCI) (NCT04772053) | GlaxoSmithKline | 2021-05-25 |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors (NCT04660929) | Carisma Therapeutics Inc | 2021-02-02 |
| Quality of Life as a Predictor of OS and PFS in Patients With Lung Cancer (NCT06900283) | Instituto Nacional de Cancerologia, Columbia | 2021-01-01 |
| Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy (NCT04655976) | GlaxoSmithKline | 2020-12-08 |
| Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment (NCT04706949) | Fudan University | 2020-12-07 |
| Baduanjin Exercise on Meridian Energy, Lung Function and Heart Rate Variability in Patients Undergoing Lung Operative. (NCT04669730) | Tzu Chi University | 2020-11-26 |
| NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer (NCT04986670) | Tufts University | 2020-11-24 |
| Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (NCT04581824) | GlaxoSmithKline | 2020-11-19 |
| Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NCT04475939) | GlaxoSmithKline | 2020-10-26 |
| Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer (NCT04592666) | Fudan University | 2020-10-09 |
| Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC (NCT04541251) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2020-08-01 |
| Appropriate Dosing to Optimise Personalised Cancer Treatments (NCT04154163) | University of Dundee | 2020-01-10 |
| Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors. (NCT04595734) | Western Sydney Local Health District | 2020-01-07 |
| Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC (NCT04069936) | WindMIL Therapeutics | 2019-10-15 |
| Retrospective Epidemiological Study of Locally Advanced Non Small Cell Lung Cancer Patients in Brazil (NCT03836469) | Latin American Cooperative Oncology Group | 2019-09-25 |
| Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer (NCT03847519) | Advaxis, Inc. | 2019-02-12 |
| Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC (NCT02824952) | Shaare Zedek Medical Center | 2018-11-01 |
| Volatil Organic Compounds in Exhaled Air and Sweat After Thoracic Surgery for Carcinological Resection (NCT03803137) | Hopital Foch | 2018-09-20 |
| Volatile Organic Compounds in Exhaled Air and Sweat of Patients Treated by Immunotherapy for Lung Cancer: Research on Biomarkers for Early Therapeutic Response (NCT03988192) | Hopital Foch | 2018-08-28 |
| Effects of VNS on RT-induced Inflammation and Prognosis of Patients With NSCLC (NCT03553485) | Vrije Universiteit Brussel | 2018-08-08 |
| Cardiac MRI Biomarker Testing (GCC 1618) (NCT02688166) | University of Maryland, Baltimore | 2018-02-01 |
| Feasibility Study of the RF Ablation Catheter to Ablate Lung Tumors (NCT03272971) | Broncus Medical Inc | 2017-12-05 |
| Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer (NCT01938456) | GlaxoSmithKline | 2013-10-01 |
| NSCLC Burden of Illness Study (NCT01772225) | GlaxoSmithKline | 2013-09-01 |
| A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor (NCT01853878) | GlaxoSmithKline | 2013-06-12 |
| Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer (NCT01471197) | Bristol-Myers Squibb | 2012-07-01 |
| An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer (NCT01362296) | GlaxoSmithKline | 2011-09-01 |
| Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery (NCT01159964) | GlaxoSmithKline | 2010-07-20 |
| Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer (NCT00871403) | GlaxoSmithKline | 2009-07-01 |
| Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma (NCT00685750) | GlaxoSmithKline | 2008-04-28 |
| A Study of Lymph Node Metastatic Pattern Based Incorporating Tumor Location, GGO Components and Size for Non-small Cell Lung Cancer (NCT06161935) | Fudan University | 2008-04-01 |
| Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer (NCT00549328) | GlaxoSmithKline | 2008-02-01 |
| A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors (NCT00619424) | GlaxoSmithKline | 2007-11-15 |
| GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer (NCT00480025) | GlaxoSmithKline | 2007-10-04 |
| A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase (NCT00528281) | GlaxoSmithKline | 2007-09-20 |
| Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer (NCT00455572) | GlaxoSmithKline | 2007-05-11 |
| Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer (NCT00390806) | GlaxoSmithKline | 2006-12-01 |
| Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer (NCT00367679) | GlaxoSmithKline | 2006-11-01 |
| A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer (NCT00073008) | GlaxoSmithKline | 2003-11-01 |
| Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer (NCT00065182) | GlaxoSmithKline | 2003-08-14 |
| Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery (NCT00290355) | GlaxoSmithKline | 2002-05-28 |
| Application of Machine Learning Algorithms to Identify Optimal Candidates for Primary Tumor Resection in Patients with Metastatic Non-small Cell Neuroendocrine Tumors (NCT06621147) | Hongquan Xing | 2000-01-01 |
| Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors (NCT06872489) | Second Life Therapeutics | |